The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

The Trump administration is reportedly considering a way to ease Medicare and Medicaid into covering GLP-1 drugs like Ozempic ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

When you only buy stocks that you have strong convictions about as long-term investments (based on sound research, your ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Ozempic has always come with side effects. The latest reported by users? Thinning hair and muscle loss. Experts break down ...

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; ...

A doctor has issued a warning to people who use weight loss jabs over the 'golden dose'. The use of GLP-1 medication, such as ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Investing.com -- Eli Lilly (NYSE: LLY) stock rose 1.3% and Novo Nordisk (NYSE: NVO) shares jumped 2% Friday morning after The ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.